Should psychiatrists use atypical antipsychotics to treat nonpsychotic anxiety?

Psychiatry

Volumn 6, Issue 6, 2009, Pages 29-37

  Pies, Ronald ^a,b  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anxiety disorder; Atypical antipsychotic; Extrapyramidal side effects; Generalized anxiety disorder; Neuroleptic malignant syndrome; Obsessive compulsive disorder; Off label; Posttraumatic stress disorder; Social anxiety disorder; Tardive dyskinesia

Indexed keywords

4 AMINOBUTYRIC ACID; AMITRIPTYLINE PLUS PERPHENAZINE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; DOPAMINE 2 RECEPTOR; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRIFLUOPERAZINE;

AKATHISIA; ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL; DEPRESSION; DNA POLYMORPHISM; DRUG APPROVAL; DRUG EFFICACY; DRUG LABELING; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FOOD AND DRUG ADMINISTRATION; GENE FUNCTION; HEART ARRHYTHMIA; HUMAN; LONG TERM CARE; METABOLIC SYNDROME X; NONHUMAN; NONPSYCHOTIC ANXIETY; OFF LABEL DRUG USE; PANIC; POSTTRAUMATIC STRESS DISORDER; SIDE EFFECT; SOCIAL PHOBIA; SUDDEN DEATH; TARDIVE DYSKINESIA; TRANQUILIZING ACTIVITY; WEIGHT GAIN;

EID: 68349128598     PISSN: 15505952     EISSN: 15555194     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Bandelow B, Zohar J, Hollander E, et al. World Federation of Society of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry. 2008;9:248-312.
2. Gao K, Muzina D, Gajwani P, Calabrese JR. Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. J Clin Psychiatry. 2006;67:1327-1340.
3. Mendels J, Krajewski TF, Huffer V, et al. Effective short-term treatment of generalized anxiety disorder with trifluoperazine. J Clin Psychiatry. 1986;47:170-174.
4. Stelazine [package insert]. Collegeville, PA: GlaxoSmithKline; 2001. Available at: http://www.fda.gov/cder/foi/label/2001/11552s112lbl.PDF. Accessed April 14, 2009.
5. Brawman-Mintzer O, Nietert PJ, Rynn M, et al. Quetiapine monotherapy in patients with GAD. In the New Research Abstract of the 159th Annual Meeting of American Psychiatric Association, Toronto, Canada, May 20-25, 2006. NR: 634.
6. Chouinard G, Bandelow B, Ahokas A, et al. Once-daily extended release quetiapine fumarate (Quetiapine XR) monotherapy in generalized anxiety disorder: a phase III, double-blind, placebo-controlled study. In the Abstract Viewer of the 46th American College of Neuropsychopharmacology Annual Meeting, Boca Raton, Florida, USA. December 9-13, 2007:25.
7. Joyce M, Khan A, Atkinson S, et al. Efficacy and safety of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder (GAD). In the New Research Abstract of the 159th Annual Meeting of American Psychiatric Association, Washington DC, USA, May 3-8, 2008. NR:3138.
8. Katzman M, Brawman-Mintzer O, Reyes E, et al. Extended release quetiapine fumarate (quetiapine XR) monotherapy in maintenance treatment of generalized anxiety disorder (GAD): efficacy and tolerability results from a randomized, placebo-controlled trial. In the New Research Abstract of the 159th Annual Meeting of American Psychiatric Association, Washington DC, USA, May 3-8, 2008. NR:3140.
9. Tefera L, Tomao LC. Anxiety. eMedicine Emergency Medicine. 2008 Nov 20. Available at: http://emedicine.medscape.com/article/805265-overview. Accessed April 14, 2009.
10. Charney DS, Drevets WC. Neurobiological basis of anxiety disorders. In: Davis KL, Charney D, Coyle JT, Nemeroff C (eds). Neuropsychopharmacology: The Fifth Generation of Progress. Philadelphia: Lippincott Williams & Wilkins; 2002:901-930.
11. Nemeroff CB. The Role of GABA in the pathophysiology and treatment of anxiety disorders. Psychopharmacol Bull. 2003;37:133-146.
12. Tiihonen J, Kuikka J, Bergström K, et al. Dopamine reuptake site densities in patients with social phobia. Am J Psychiatry. 1997;154:239-242.
13. Voisey J, Swagell CD, Hughes IP, et al. The DRD2 gene 957C>T polymorphism is associated with posttraumatic stress disorder in war veterans, compared with controls. Depress Anxiety. 2009;26:28-33.
14. Michel FJ, Trudeau LE. Clozapine inhibits synaptic transmission at GABAergic synapses established by ventral tegmental area neurones in culture. Neuropharmacology. 2000;39:1536-1543.
15. Locchi F, Dall'olio R, Gandolfi O, Rimondini R. Olanzapine counteracts stress-induced anxiety-like behavior in rats. Neurosci Lett. 2008;438:146-149.
16. Kapur S, Zipursky R, Jones C, et al. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry. 2000;57:553-559.
17. Zarrindast MR, Valizadegan F, Rostami P, Rezayof A. Histaminergic system of the lateral septum in the modulation of anxiety-like behaviour in rats. Eur J Pharmacol. 2008;583:108-114.
18. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002;302:381-389.
19. Eison AS, Eison MS. Serotonergic mechanisms in anxiety. Prog Neuropsychopharmacol Biol Psychiatry. 1994;18(1):47-62.
20. Trivedi MH, Thase ME, Fava M, et al. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features. J Clin Psychiatry. 2008;69:1928-1936.
21. Simon NM, Connor KM, LeBeau RT, et al. Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. Psychopharmacology (Berl). 2008;197:675-681.
22. Merideth C, Cutler A, Neijber A, et al. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in the treatment of generalized anxiety disorder. Eur Neuropsychopharmacol. 2008;18:S499-S500.
23. Pollack MH, Simon NM, Zalta AK, et al. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry. 2006;59:211-215.
24. Brawman-Mintzer O, Knapp RG, Nietert PJ. Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry. 2005;66:1321-1325.
25. Pandina GJ, Canuso CM, Turkoz I, et al. Adjunctive risperidone in the treatment of generalized anxiety disorder: a double-blind, prospective, placebo-controlled, randomized trial. Psychopharmacol Bull. 2007;40(3):41-57.
26. Sheehan DV, McElroy SL, Harnett-Sheehan K, et al. Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety. J Affect Disorder. In press.
27. Shapira NA, Ward HE, Mandoki M, et al. A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol Psychiatry. 2004;55:553-555.
28. Bystritsky A, Ackerman DL, Rosen RM, et al. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J Clin Psychiatry. 2004;65:565-568.
29. Denys D, de Geus F, van Megen HJ, Westenberg HG. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry. 2004;65:1040-1048.
30. Carey PD, Vythilingum B, Seedat S, et al. Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study. BMC Psychiatry. 2005 Jan 24;5:5.
31. McDougle CJ, Epperson CN, Pelton GH, et al. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry. 2000;57:794-801.
32. Hollander E, Baldini Rossi N, Sood E, Pallanti S. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2003;6:397-401.
33. Li X, May RS, Tolbert LC, et al. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. J Clin Psychiatry. 2005;66:736-743.
34. Erzegovesi S, Guglielmo E, Siliprandi F, Bellodi L. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study. Eur Neuropsychopharmacol. 2005;15:69-74.
35. Butterfield MI, Becker ME, Connor KM, et al. Olanzapine in the treatment of post-traumatic stress disorder: a pilot study. Int Clin Psychopharmacol. 2001;16:197-203.
36. Stein MB, Kline NA, Matloff JL. Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. Am J Psychiatry. 2002;159:1777-1779.
37. Hamner MB, Faldowski RA, Ulmer HG, et al. Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms. Int Clin Psychopharmacol. 2003;18:1-8.
38. Bartzokis G, Lu PH, Turner J, et al. Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder. Biol Psychiatry. 2005;57:474-479.
39. Padala PR, Madison J, Monnahan M, et al. Risperidone monotherapy for post-traumatic stress disorder related to sexual assault and domestic abuse in women. Int Clin Psychopharmacol. 2006;21:275-280.
40. Barnett SD, Kramer ML, Casat CD, et al. Efficacy of olanzapine in social anxiety disorder: a pilot study. J Psychopharmacol. 2002;16:365-368.
41. Vaishnavi S, Alamy S, Zhang W, et al. Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1464-1469.
42. Waknine Y. Off-label use of atypical antipsychotics linked to increased mortality in elderly. Medscape Alert. 2005 April 12. Available at: http://www.medscape.com/viewarticle/502902. Accessed April 14, 2009.
43. Posternak M. Prescribing atypical antipsychotics: what are the risks? The Carlat Psychiatry Report. 2009;7:3-8.
44. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161:414-425.
45. Gao K, Kemp DE, Ganocy SJ, et al. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol. 2008;28:203-209.
46. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19 Suppl 1:1-93.
47. Saddichha S, Manjunatha N, Ameen S, Akhtar S. Metabolic syndrome in first episode schizophrenia - a randomized double-blind controlled, short-term prospective study. Schizophr Res. 2008;101(1-3):266-272.
48. Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;36:225-235.
49. Mackin P, Young AH. QTc interval measurement and metabolic parameters in psychiatric patients taking typical or atypical antipsychotic drugs: a preliminary study. J Clin Psychiatry. 2005;66:1386-1391.
50. Reeves RR. Abuse of olanzapine by substance abusers. J Psychoactive Drugs. 2007;39:297-299.
51. Murphy D, Bailey K, Stone M, Wirshing WC. The addictive potential of quetiapine. Am J Psychiatry. 2008;165:918.